CD8lowCD28– T Cells: A Human CD8 T-Suppressor Subpopulation with Alloantigen Specificity Induced by Soluble HLA-A2 Dimer in Vitro

CD8+ suppressor T cells have been demonstrated to provide protection of allografts from rejection. We previously reported that soluble peptide/HLA-A2 dimer shows peptide-specific inhibitory effects on alloresponse in a coculture of peptide-pulsed T2 cells with HLA-A2 negative lymphocytes in vitro. Here we found a subset of CD8lowCD28– T cells that was induced in the dimer-treated coculture. Importantly, this population showed hyporesponsiveness to the alloantigen restimulation as well as alloantigen-specific suppression on alloreactive T cells in a cell–cell contact-dependent fashion. The suppressive mechanisms of CD8lowCD28– T cells involved an elevated expression of membrane-bound TGF-β1, but not Foxp3, CTLA-4, or IL-10. Furthermore, an over-represention of CD8lowCD28– T cells was observed in the patients after allogeneic platelet transfusion and positively correlated with the elevated concentrations of plasma HLA class I antigens. Our findings demonstrated that soluble HLA-A2 dimer could efficiently induce the tolerant CD8lowCD28– T cells with alloantigen-specific suppression on alloreactive T cells. This study might provide a new strategy for preparation of donor-specific suppressor T cells and represent an attractive alternative for induction of allograft tolerance.

[1]  C. Bona,et al.  Dimeric MHC-peptides inserted into an immunoglobulin scaffold as new immunotherapeutic agents , 2011, Journal of cellular and molecular medicine.

[2]  Jeffrey N. Martin,et al.  HIV disease progression correlates with the generation of dysfunctional naive CD8(low) T cells. , 2011, Blood.

[3]  R. Lechler,et al.  Regulatory T cells as therapeutic cells , 2008, Current opinion in organ transplantation.

[4]  F. Lemonnier,et al.  Role of class I human leukocyte antigen molecules in early steps of echovirus infection of rhabdomyosarcoma cells. , 2008, Virology.

[5]  B. Hahn,et al.  Induction of immune tolerance by activation of CD8+ T suppressor/regulatory cells in lupus-prone mice. , 2008, Human immunology.

[6]  S. Ferrone,et al.  Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. , 2008, Tissue antigens.

[7]  R. Flavell,et al.  TGF-β: A Master of All T Cell Trades , 2008, Cell.

[8]  T. Ottenhoff,et al.  Human Anti-Inflammatory Macrophages Induce Foxp3+GITR+CD25+ Regulatory T Cells, Which Suppress via Membrane-Bound TGFβ-11 , 2008, The Journal of Immunology.

[9]  D. Vignali,et al.  How regulatory T cells work , 2008, Nature Reviews Immunology.

[10]  N. Jones,et al.  Presence of Suppressor HIV-Specific CD8+ T Cells Is Associated with Increased PD-1 Expression on Effector CD8+ T Cells1 , 2008, The Journal of Immunology.

[11]  N. Rouas-Freiss,et al.  CD3+CD4low and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. , 2007, Blood.

[12]  Zhihui Liang,et al.  Peptide-Dependent Inhibition of Alloreactive T-Cell Response by Soluble Divalent HLA-A2/IgG Molecule In Vitro , 2007, Transplantation.

[13]  A. Rudensky,et al.  TGFβ signalling in control of T-cell-mediated self-reactivity , 2007, Nature Reviews Immunology.

[14]  N. Zavazava,et al.  A Divalent Human Leukocyte Antigen-B7 Fusion-Protein Up-regulates CD25 and CD69 in Alloreactive CD8+ T Cells Bypassing CD28 Costimulation , 2006, Transplantation.

[15]  B. Cairns,et al.  Low‐avidity CD8lo T cells induced by incomplete antigen stimulation in vivo regulate naive higher avidity CD8hi T cell responses to the same antigen , 2006, European journal of immunology.

[16]  M. Matyszak,et al.  Autoreactive human peripheral blood CD8+ T cells with a regulatory phenotype and function , 2005, European journal of immunology.

[17]  C. Bona,et al.  Soluble, dimeric HLA DR4‐peptide chimeras: An approach for detection and immunoregulation of human type‐1 diabetes , 2005, European journal of immunology.

[18]  A. Kelso,et al.  Progressive Differentiation and Commitment of CD8+ T Cells to a Poorly Cytolytic CD8low Phenotype in the Presence of IL-41 , 2005, The Journal of Immunology.

[19]  A. Dejean,et al.  Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation. , 2004, Blood.

[20]  D. Mancini,et al.  Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. , 2004, International immunology.

[21]  A. O’Garra,et al.  Regulatory T cells and mechanisms of immune system control , 2004, Nature Medicine.

[22]  A. Kelso,et al.  Profiling the CD8low phenotype, an alternative career choice for CD8 T cells during primary differentiation , 2004, Immunology and cell biology.

[23]  J. Bluestone,et al.  Peptide-MHC Class II Dimers as Therapeutics to Modulate Antigen-Specific T Cell Responses in Autoimmune Diabetes1 , 2003, The Journal of Immunology.

[24]  C. Akdis,et al.  Human CD8 T cells of the peripheral blood contain a low CD8 expressing cytotoxic/effector subpopulation , 2003, Immunology.

[25]  M. Colonna,et al.  Tolerization of dendritic cells by TS cells: the crucial role of inhibitory receptors ILT3 and ILT4 , 2002, Nature Immunology.

[26]  J. Frelinger,et al.  HIV Antigens Can Induce TGF-β1-Producing Immunoregulatory CD8+ T Cells1 , 2002, The Journal of Immunology.

[27]  S. Casares,et al.  Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide–MHC class II chimera , 2002, Nature Immunology.

[28]  A. Kelso,et al.  A Clonal Culture System Demonstrates That IL-4 Induces a Subpopulation of Noncytolytic T Cells with Low CD8, Perforin, and Granzyme Expression1 , 2002, The Journal of Immunology.

[29]  W. Strober,et al.  Cell Contact–Dependent Immunosuppression by Cd4+Cd25+Regulatory T Cells Is Mediated by Cell Surface–Bound Transforming Growth Factor β , 2001, The Journal of experimental medicine.

[30]  H. Kuwano,et al.  Clinical significance of soluble form of HLA class I molecule in Japanese patients with pancreatic cancer. , 2001, Human immunology.

[31]  P. Berloco,et al.  Organ allograft recipients develop HLA class I-specific T suppressor cells. , 2001, Transplantation Proceedings.

[32]  M. Grisotto,et al.  Most parasite‐specific CD8+ cells in Trypanosoma cruzi‐infected chronic mice are down‐regulated for T‐cell receptor‐αβ and CD8 molecules , 2001 .

[33]  W. Burlingham.  Soluble MHC, immunoregulation, and tolerance: a progress report. , 2000, Human immunology.

[34]  G. Pirozzi,et al.  Increased serum concentrations of soluble HLA-class I antigens in hepatitis C virus related mixed cryoglobulinaemia , 2000, Annals of the rheumatic diseases.

[35]  Alexander Miller,et al.  Antigen-Specific Signaling by a Soluble, Dimeric Peptide/Major Histocompatibility Complex Class II/Fc Chimera Leading to T Helper Cell Type 2 Differentiation , 1999, The Journal of experimental medicine.

[36]  G. Filaci,et al.  Soluble HLA Class I, HLA Class II, and Fas Ligand in Blood Components: A Possible Key to Explain the Immunomodulatory Effects of Allogeneic Blood Transfusions , 1999 .

[37]  C. Thompson,et al.  IL-4 enhances long-term survival of CD28-deficient T cells. , 1998, Journal of immunology.

[38]  A. Kelso,et al.  A single peripheral CD8+ T cell can give rise to progeny expressing type 1 and/or type 2 cytokine genes and can retain its multipotentiality through many cell divisions. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Shabanowitz,et al.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.

[40]  M. Barnardo,et al.  Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). , 1995, Tissue antigens.

[41]  A. Sette,et al.  Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope , 1994, The Journal of experimental medicine.

[42]  D. Tuveson,et al.  A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Rotter,et al.  Epstein-Barr virus transformation of cryopreserved lymphocytes: prolonged experience with technique. , 1991, American journal of human genetics.

[44]  M. Bevan,et al.  Defective presentation of endogenous antigen by a cell line expressing class I molecules. , 1990, Science.

[45]  J. Strominger,et al.  The human HLA specific monoclonal antibody W6/32 recognizes a discontinuous epitope within the α2 domain of murine H-2Db , 1986, Immunogenetics.

[46]  R. Coffman,et al.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. , 1986, Journal of immunology.

[47]  P. Morris,et al.  Alloimmunisation to HLA Antigens following Transfusion with Leucocyte‐Poor and Purified Platelet Suspensions , 1985, Vox sanguinis.

[48]  C. Schiffer,et al.  Alloimmunization following platelet transfusion: the absence of a dose- response relationship , 1981 .

[49]  R. Charlton,et al.  Soluble HL-A7 Antigen: Localization in the β-Lipoprotein Fraction of Human Serum , 1970, Science.

[50]  R. Gershon,et al.  Cell interactions in the induction of tolerance: the role of thymic lymphocytes. , 1970, Immunology.

[51]  J. J. Rood,et al.  Anti HL-A2 Inhibitor in Normal Human Serum , 1970, Nature.

[52]  Supporting Online Material , 2002 .

[53]  M. Blajchman,et al.  The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions. , 1995, Blood.